XML 43 R7.htm IDEA: XBRL DOCUMENT

Business Overview	9 Months Ended
Business Overview	Sep. 30, 2013
Business Overview
Business Overview	1. Business Overview Synergy Pharmaceuticals Inc. (“Synergy” or “the Company”) is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its lead product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant-irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by low bowel movement frequency. A majority of these patients additionally report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C is characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. Synergy is also developing SP-333, a second generation GC-C receptor agonist for the treatment of gastrointestinal disorders and diseases, including opioid-induced constipation, or OIC, and the inflammatory bowel disease ulcerative colitis, or UC.